

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

The logo for LINC (Leipzig Interventional Course) features the letters 'L I N C' in a bold, sans-serif font. A large, stylized, blue brushstroke graphic sweeps across the letters from the bottom left to the top right, partially overlapping them.

Eric Secemsky

Page 1/2

Wednesday, January 27, 2021

MAIN ARENA 1

- 19:00 – 20:20** **VIVA/LINC – Joint session on the current status and future of drug-eluting therapies**
MODERATOR:
Dierk Scheinert
Peter Schneider
PANEL:
Andrew Holden
Marianne Brodmann
Robert Lookstein
- 19:00 – 19:03 Introduction by the moderators
Dierk Scheinert
Peter Schneider
- 19:03 – 19:08 Insights on paclitaxel safety from the femoral-popliteal RCTs
Peter Schneider
- 19:08 – 19:13 Insights on paclitaxel safety from femoral-popliteal real-world data
Eric Secemsky
- 19:13 – 19:18 How does the Voyager data help us understand the risks of paclitaxel?
Marc Bonaca
- 19:18 – 19:23 Paclitaxel safety in patients with CLTI
Marianne Brodmann
- 19:23 – 19:28 Newly FDA-approved paclitaxel devices for lower extremity and dialysis and the regulatory implications
Robert Lookstein
- 19:28 – 19:33 New data on paclitaxel in the next couple of years; what should we expect?
Eva Freisinger
- 19:33 – 19:45 Panel discussion
- 19:45 – 19:50 Paclitaxel vs. limus agents. Mechanism of action, what are the challenges to move beyond paclitaxel?
Sahil Parikh

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Eric Secemsky

Page 2/2

Wednesday, January 27, 2021

- | | |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 19:50 – 19:55 | Previous experience with limus compounds in the non-coronary arteries; lessons learned
Thomas Zeller |
| 19:55 – 20:00 | New limus delivering devices for above and below knee occlusive disease; when to expect results?
Andrew Holden |
| 20:00 – 20:10 | Blue horizon keynote speech: Potential for drug delivery in the treatment of lower extremity occlusive disease: what will the practice look like in 5 years?
Dierk Scheinert |
| 20:10 – 20:20 | Panel discussion |

We are asking all faculty members to strictly respect the given time limits.